SCI Abstract

search
+
Contemporary CMML Risk Stratification and Management
Contemporary CMML Risk Stratification and Management
Chronic myelomonocytic leukemia (CMML), a rare myelodysplastic/myeloproliferative neoplasm (MDS/MPN) overlap syndrome, pos...
Allogeneic Transplant for CMML
Allogeneic Transplant for CMML
Chronic myelomonocytic leukemia (CMML) is a rare hematologic malignancy at the intersection of myelodysplastic (MDS) and m...
Use of Patient-Centered Technology and Digital Interventions in Pediatric and Adult Patients with Hematologic Malignancies
Use of Patient-Centered Technology and Digital Interventions in Pediatric and Adult Patients with Hematologic Malignancies
As society continues to advance in technology, it is important to address how this advancement can impact and enhance pati...
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia
Novel Approaches to Managing Patients with Relapsed and Refractory Waldenström Macroglobulinemia
Waldenström macroglobulinemia is a rare non-Hodgkin lymphoma (NHL) characterized by lymphoplasmacytic bone marrow inf...
Systemic Mastocytosis: State of the Art
Systemic Mastocytosis: State of the Art
Since identification of Systemic mastocytosis (SM) as a distinct disease entity by the World Health Organisation (WHO), th...
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicals
In this review, we aim to explore the optimal approach to patients presenting with eosinophilia, considering recent advanc...
Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders
Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders
Telomere biology disorders (TBD) are a group of genetic disorders characterized by premature shortening of telomeres, resu...
JAK Inhibitors for Myelofibrosis: Strengths and Limitations
JAK Inhibitors for Myelofibrosis: Strengths and Limitations
The landscape of myelofibrosis (MF) has changed since the discovery of the JAK2 V617F mutation and subsequent development ...
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma
Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma
The introduction of bispecific antibodies is one of the most significant recent advances in the treatment of relapsed/refr...
Disparities in Clinical Trial Enrollment– Focus on CAR-T and Bispecific Antibody Therapies
Disparities in Clinical Trial Enrollment– Focus on CAR-T and Bispecific Antibody Therapies
Recent studies show that unresolved disparities hinder enrollment to clinical trials, equitable distribution of treatments...
Monoclonal Gammopathy-Associated Neuropathy
Monoclonal Gammopathy-Associated Neuropathy
Peripheral neuropathy (PN) is more commonly seen in individuals with monoclonal gammopathies, especially in patients with ...
Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies
Navigating the Economic Burden of Multiple Myeloma: Insights into Cost-effectiveness of CAR-T and Bispecific Antibody Therapies
Multiple myeloma is a chronic malignancy and with evolving treatment options, understanding the economic burden and cost-e...
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications
Mutant Calreticulin in MPN: Mechanistic Insights and Therapeutic Implications
More than a decade following the discovery of Calreticulin (CALR) mutations as drivers of myeloproliferative neoplasms (MP...
Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes
Role of Population Based Studies in Advancing our Knowledge of Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are myeloid neoplasms characterized by high molecular and genomic heterogeneity. According...
Blinatumomab in Practice
Blinatumomab in Practice
Acute lymphoblastic leukemia (ALL) is a rare hematologic neoplasm in adults, with most cases defined by pathology related ...
Novel Biomarkers and Molecular Targets in ALL
Novel Biomarkers and Molecular Targets in ALL
Acute lymphoblastic leukemia (ALL) is a widely heterogeneous disease in terms of genomic alterations, treatment options, a...
Unlocking the Potential of Artificial Intelligence in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Unlocking the Potential of Artificial Intelligence in Acute Myeloid Leukemia and Myelodysplastic Syndromes
This review aims to elucidate the transformative impact and potential of machine learning (ML) in the diagnosis, prognosis...
Measurable Residual Disease Monitoring in Lymphoma
Measurable Residual Disease Monitoring in Lymphoma
The utility of analyzing circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and disease in the bone marrow as ...
Experimental and Computational Approaches to Measure Telomere Length: Recent Advances and Future Directions
Experimental and Computational Approaches to Measure Telomere Length: Recent Advances and Future Directions
The length of telomeres, protective structures at the chromosome ends, is a well-established biomarker for pathological co...
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders
Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders
Mature T/NK-cell neoplasms comprise a heterogeneous group of diseases with diverse clinical, histopathologic, immunophenot...
Genetic Counseling and Family Screening Recommendations in Patients with Telomere Biology Disorders
Genetic Counseling and Family Screening Recommendations in Patients with Telomere Biology Disorders
Telomere biology disorders (TBDs) encompass a spectrum of genetic diseases with a common pathogenesis of defects in telome...
NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition
NK Cell Therapeutics for Hematologic Malignancies: from Potential to Fruition
The current review focuses on the preclinical development and clinical advances of natural killer (NK) cell therapeutics f...
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia
An Update on the Management of Advanced Phase Chronic Myeloid Leukemia
While most patients with chronic myeloid leukemia (CML) present in a chronic phase and are expected to have a normal life ...
Central Nervous System Relapse in T and NK cell Lymphomas
Central Nervous System Relapse in T and NK cell Lymphomas
T and NK cell lymphomas are relatively rare and heterogeneous forms of non-Hodgkin lymphoma that are associated with high ...
EBV Reactivation and Lymphomagenesis: More Questions than Answers
EBV Reactivation and Lymphomagenesis: More Questions than Answers
Epstein-Barr Virus (EBV) is a ubiquitous herpesvirus that affects almost all humans and establishes lifelong infections by...
Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma
Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma
Largely, treatment advances in relapsed and/or refractory acute lymphoblastic leukemia (ALL) have been made in B cell dise...
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions
Financial Toxicity in Patients with Hematologic Malignancies: a Review and Need for Interventions
Financial toxicity is a developing research area to quantify the financial stress experienced by patients and caregivers, ...
Multiple Myeloma: Current Clinical Landscape and Compounding Costs
Multiple Myeloma: Current Clinical Landscape and Compounding Costs
The treatment landscape of multiple myeloma (MM) has evolved resulting in MM becoming a chronic condition. The costs of MM...
Real-world Management of CML: Outcomes and Treatment Patterns
Real-world Management of CML: Outcomes and Treatment Patterns
Chronic myeloid leukemia (CML) is a disease that previously signified a poor prognosis, but treatment options and outcomes...
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases
A Journey Through JAK Inhibitors for the Treatment of Myeloproliferative Diseases
Chronic myeloproliferative neoplasms (MPN) represent a group of diseases characterised by constitutive activation of the J...
Load More
format_indent_increase